Frequency of DNA-HPV-HR by automated PCR method (COBAS®) in our cervical patients from a population in Proboquilla-Cartagena, Colombia
Frecuencia de DNA-HPV-HR por método automatizado PCR (COBAS®) en nuestras cervicouterinas de una población en Proboquilla-Cartagena, Colombia
Article Sidebar
PDF (Español (España))
FLIP
How to Cite
Puerto de Amaya, M., Olaya, M., Pérez, C. H., Falla, S., & Castillo, N. D. (2014). Frequency of DNA-HPV-HR by automated PCR method (COBAS®) in our cervical patients from a population in Proboquilla-Cartagena, Colombia. Journal of Medicine and Surgery Repertoire, 23(3), 209–214. https://doi.org/10.31260/RepertMedCir.v23.n3.2014.711
Section
Research Article
License terms
Main Article Content
Abstract
Objective: to determine DNA-HPV-HR by automated PCR method (cobas®) in cervical samples from a population in Proboquilla, Cartagena, Colombia. Methods: series of cases of women who attended the campaign where conventional cytology was taken and a second sample in a vial to determine HPV-HR DNA through the polymerase chain reaction (PCR). Results: 31 samples of cervico-uterine cytology were collected, the PCR test was positive in six; 4 cases with simple infection and 2 with multiple infection. One of the latter was positive for the three groups (HR-HPV, HPV-16, HPV-18) and the other for two (HR-HPV and HPV-18). Conclusion: a group of women infected with HPVs classified as high risk, with simple and multiple infection, who were referred to gynecology. HPV-HR infection was confirmed in 5: 7 cytology results classified as ASC-US.
Keywords:
Downloads
Download data is not yet available.
Article Details
References
1. Almonte M, Murillo R, Sánchez GI, Jerónimo J, Salmerón J, Ferreccio C, et al. Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina. Salud pública Méx. 2010;52(6): 544-59.
2. Mckinley E. Principios generales de citologia. En: Atkinson BF, editor. Atlas de diagnóstico citopatológico. Madrid: Elsevier; 2005. p. 1-30.
3. Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA. 1989; 261(5):737-43.
4. Denny L. The prevention of cervical cáncer in developping countries. BJOG. 2005;112(9):1204-12.
5. Agorastos T. Auto-toma de muestras para la realización del VPH: facilitando el acceso a los servicios sanitarios. HPV Today. 2007 Feb; 10: 12.
6. Kumar VA, Abbas AK. Robbins and Cotran pathologic basis of disease. 7a ed. Philadelphia: Elsevier Saunders; 2005.
7. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol. 2003;77(19):10186-201.
8. DeMay RM. The pap smear. In: ASCP, editor. The art and science of Cytopathology. Chicago : ASCP Press;1996. p. 61-172.
9. Sadeghi SB, Sadeghi A, Robboy SJ. Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population. Cancer. 1988;61(11):2359-61.
10. Muñoz N, Bravo LE. Epidemiología del cáncer de cuello uterino en Colombia. Colomb Med. 2012;43(4):298-304.
11. Bosch FX, Rohan T, Schneider A, Frazer I, Pfister H, Castellsagué X et al. Papillomavirus research update: highlights of the Barcelona HPV international papillomavirus conference. J Clin Pathol. 2001; 54:163-75.
12. Piñeros Petersen M, Murillo Moreno RH. Incidencia de cancer en Colombia: importancia de las fuentes de nformacion en las obtencion de cifras estimativas. Rev Col Cancerol. 2004; 8(1): 5-14.
13. Colombia. Ministerio de Salud. Resolución 412 de Febrero 25 de 2000 por la cual se establecen las actividades, procedimientos e intervenciones de demanda inducida y obligatorio cumplimiento y se adoptan las normas técnicas y guías de atención para el desarrollo de las acciones de protección específica y detección temprana y la atención de enfermedades de interés en salud pública.
14. Rodríguez Costa J, Sáez de Santamaría J, De Agustín Vázquez D. Citología líquida. Madrid : Díaz de Santos, c2006.
15. Cuzick J. Test de VPH versus cribado cervical convencional. Cribado del VPH. HPV Today. 2007 Feb; 10: 5.
16. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-88.
17. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83(2):439-44.
18. Schneider A, Hoyer H, Lotz B, Leistritza S, Kühne-Heid R, Nindl I, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89(6):529-34.
19. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98(11):765-74.
20. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet oncol. 2006;7(7):547-55.
21. Colombia. Ministerio de Salud y Protección Social para el control del cáncer del cuello uterino, (2013-2020). Bogotá: El Ministerio; 2012.
22. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
23. Garcia DA, Schmitt M, Cid Arregui A, Castillo M, Briceño I, Aristizabal FA. Genotipificación del virus del papiloma humano (VPH) en muestras de cepillados cervicales de pacientes de diferentes hospitales de Bogotá y evaluación de la concordancia de dos métodos basados en PCR. Rev Colomb Obstet Ginecol. 2010; 61(04):310-8.
24. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796-802.
25. Nasser H, Hayek S, Balasubramaniam M, Kuntzman TJ. Infectious organisms on Papanicolaou smears should not influence the diagnosis of atypical Squamous cells of undetermined Significance. Acta Cytol. 2011;55(3):251-4.
26. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002 Apr; 55(4):244-65.
27. Castaneda Iñiguez MS, Toledo Cisneros R, Aguilera Delgadillo M. Factores de riesgo para cancer cervicouterino en mujeres de Zacatecas. Salud Publica Mex. 1998;40(4):330-8.
28. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000;284(6):706-12.
2. Mckinley E. Principios generales de citologia. En: Atkinson BF, editor. Atlas de diagnóstico citopatológico. Madrid: Elsevier; 2005. p. 1-30.
3. Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA. 1989; 261(5):737-43.
4. Denny L. The prevention of cervical cáncer in developping countries. BJOG. 2005;112(9):1204-12.
5. Agorastos T. Auto-toma de muestras para la realización del VPH: facilitando el acceso a los servicios sanitarios. HPV Today. 2007 Feb; 10: 12.
6. Kumar VA, Abbas AK. Robbins and Cotran pathologic basis of disease. 7a ed. Philadelphia: Elsevier Saunders; 2005.
7. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol. 2003;77(19):10186-201.
8. DeMay RM. The pap smear. In: ASCP, editor. The art and science of Cytopathology. Chicago : ASCP Press;1996. p. 61-172.
9. Sadeghi SB, Sadeghi A, Robboy SJ. Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population. Cancer. 1988;61(11):2359-61.
10. Muñoz N, Bravo LE. Epidemiología del cáncer de cuello uterino en Colombia. Colomb Med. 2012;43(4):298-304.
11. Bosch FX, Rohan T, Schneider A, Frazer I, Pfister H, Castellsagué X et al. Papillomavirus research update: highlights of the Barcelona HPV international papillomavirus conference. J Clin Pathol. 2001; 54:163-75.
12. Piñeros Petersen M, Murillo Moreno RH. Incidencia de cancer en Colombia: importancia de las fuentes de nformacion en las obtencion de cifras estimativas. Rev Col Cancerol. 2004; 8(1): 5-14.
13. Colombia. Ministerio de Salud. Resolución 412 de Febrero 25 de 2000 por la cual se establecen las actividades, procedimientos e intervenciones de demanda inducida y obligatorio cumplimiento y se adoptan las normas técnicas y guías de atención para el desarrollo de las acciones de protección específica y detección temprana y la atención de enfermedades de interés en salud pública.
14. Rodríguez Costa J, Sáez de Santamaría J, De Agustín Vázquez D. Citología líquida. Madrid : Díaz de Santos, c2006.
15. Cuzick J. Test de VPH versus cribado cervical convencional. Cribado del VPH. HPV Today. 2007 Feb; 10: 5.
16. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-88.
17. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83(2):439-44.
18. Schneider A, Hoyer H, Lotz B, Leistritza S, Kühne-Heid R, Nindl I, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89(6):529-34.
19. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98(11):765-74.
20. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet oncol. 2006;7(7):547-55.
21. Colombia. Ministerio de Salud y Protección Social para el control del cáncer del cuello uterino, (2013-2020). Bogotá: El Ministerio; 2012.
22. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
23. Garcia DA, Schmitt M, Cid Arregui A, Castillo M, Briceño I, Aristizabal FA. Genotipificación del virus del papiloma humano (VPH) en muestras de cepillados cervicales de pacientes de diferentes hospitales de Bogotá y evaluación de la concordancia de dos métodos basados en PCR. Rev Colomb Obstet Ginecol. 2010; 61(04):310-8.
24. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796-802.
25. Nasser H, Hayek S, Balasubramaniam M, Kuntzman TJ. Infectious organisms on Papanicolaou smears should not influence the diagnosis of atypical Squamous cells of undetermined Significance. Acta Cytol. 2011;55(3):251-4.
26. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002 Apr; 55(4):244-65.
27. Castaneda Iñiguez MS, Toledo Cisneros R, Aguilera Delgadillo M. Factores de riesgo para cancer cervicouterino en mujeres de Zacatecas. Salud Publica Mex. 1998;40(4):330-8.
28. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000;284(6):706-12.